Ailanthus altissima bark extract, quassin compound, and preparation method, application and pharmaceutical composition of ailanthus altissima bark extract and quassin compound
By extracting and isolating the quassin-like compound L1 from the bark of the tree as a JAK2 inhibitor, the lack of effective treatments for triple-negative breast cancer has been addressed, achieving inhibition and apoptosis induction of triple-negative breast cancer cells and providing a new treatment strategy.
Patent Information
- Application Number
- CN202511490574.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-17
- Publication Date
- 2025-11-18
AI Technical Summary
Current treatment options for triple-negative breast cancer are limited, especially the lack of safe and effective endocrine therapy and HER2-targeted therapy, which leads to poor prognosis and early metastasis. Therefore, new treatment strategies need to be found.
L1, a quassin-like compound, was extracted from the bark of *Toona sinensis*. The compound was prepared by reflux extraction, silica gel column chromatography, and thin-layer chromatography. L1, which has JAK2 inhibitor activity, can bind to JAK2 protein with high affinity, block JAK2 kinase activity and its downstream STAT3 signaling pathway, inhibit the proliferation of triple-negative breast cancer cells and induce apoptosis.
Compound L1, as a novel JAK2 inhibitor, can significantly inhibit the proliferation and colony formation of triple-negative breast cancer cells and induce cancer cell apoptosis, providing a new targeted therapy strategy for triple-negative breast cancer and showing good application prospects.